SBIR/STTR Research Award
POC Diagnostic for Gonorrhea and Determination of Antimicrobial Susceptibility
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Visby Medical, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LWNQZECSVHY1
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
VisbyFormally know as Click Diagnosticshas developed a PCR based rapiddisposablepoint of care test that automatically performs sample processingPCR amplificationand amplicon detectionLeveraging the existing platformClick willfrom a single urogenital sampledetect NG and determine whether the infecting strain is susceptible to three classes of antibioticsciprofloxacincefiximeor a novel antibiotic zoliflodacinBecause of the gonococci s ability to become resistant to almost every recommended antibioticonly one therapy is currently recommended by the CDCdual treatment with injectable ceftriaxone and oral azithromycinthough reduced susceptibility has been observed for bothBy determining the genotype of the infecting strainWT gyraseA Serciprofloxacin susceptibleor penA mosaic XXXIVreduced cefixime susceptibilitywe will be providing individualized treatment to patientsthus minimizing the use of ceftriaxoneAdditionallyby detecting zoliflodacin resistant genotypesgyraseB DN KT SNwe now have a companion diagnostic for this novel class of antibioticIn Phase IClick has partnered with DrJeffrey KlausnerUCLAto develop and test a multiplexed antimicrobial susceptibility assay to detect single nucleotide polymorphisms that confer susceptibility resistance to ciprofloxacincefiximeand zoliflodacinThe new assay will retain similar specificitysensitivityPCR efficiencyand limits of detectioncfu mlas our current NG opaA assay
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development, Preclinical and Preanalytical Evaluation of a Rapid Point-of-Care NAAT Device to determine Ciprofloxacin Sensitivity of Gonococci in Urogenital Samples
- Commercialization of low cost, disposable, point-of-care molecular diagnostic device for sexually transmitted infections
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients